Clinical trials: Atherosclerotic Disease
Lipoprotein Disorder
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
This is a phase 2, double-blind, randomized, placebo-controlled, multi-center, dose-finding study to evaluate the efficacy and safety of Kylo-11 administered subcutaneously compared to placebo in participants with ASCVD and…
- Trial name
- NCT07327840
- Where
- 48 sites in United States, China
- Volunteers
- 204 people
- Sponsor
- Kylonova (Xiamen) Biopharma co., LTD.